Antibody therapy articles from across Nature Portfolio

Antibody therapies are a type of biologic. They are typically monoclonal antibodies selected to bind to a particular protein (often a cell-surface protein), and produced using recombinant DNA technology.

Latest Research and Reviews

News and Comment

  • News & Views |

    Clinical utility of T cell engagers (TCEs) in cancer immunotherapy for solid tumors is hampered by on-target off-tumor activity and dose-limiting adverse events. A study now proposes a solution to tackle these challenges through the design and preclinical characterization of extended half-life TCEs that are conditionally activated in the tumor microenvironment.

    • Aliyah B. Silver
    • , Jeremy Wang
    •  & Jamie B. Spangler
    Nature Cancer 4, 439-441
  • Research Highlights |

    Different Notch ligands have opposing roles in regulating the proliferation and differentiation of vascular smooth muscle cells in the pulmonary vasculature in pulmonary arterial hypertension. Selectively targeting Jagged 1–NOTCH3 signalling might be an effective and safe strategy for the treatment of this condition.

    • Irene Fernández-Ruiz
  • News & Views |

    Patients with KRAS-mutant colorectal cancers do not respond to cetuximab, a monoclonal antibody against EGFR. A new proof-of-concept study presents a bispecific antibody with the ability to trigger EGFR degradation in LGR5+ cancer stem cells, and robust anti-tumor activity in KRAS-mutant and wild-type colorectal cancers.

    • Norihiro Goto
    •  & Ömer H. Yilmaz
    Nature Cancer 3, 379-380
  • News & Views |

    Increasingly, human monoclonal antibodies have been deployed against COVID-19, but combinations are typically needed for recognition of diverse viral variants. Bispecific antibodies could make the task of manufacturing and delivering combinations more efficient.

    • James E. Crowe Jr
    Nature Immunology 23, 346-347